Zentiva Transitions Ownership to GTCR After Advent's Successful Transformation

Zentiva's Ownership Transition: A New Era Ahead

In a significant development in the pharmaceutical sector, Zentiva, a leading European manufacturer of generics, is transitioning to new ownership as GTCR acquires the company from private equity firm Advent. This move, announced on September 12, 2025, marks a pivotal moment for Zentiva, which has seen remarkable growth and transformation under Advent's stewardship since its acquisition from Sanofi in 2018.

The Growth Journey of Zentiva

Advent played a crucial role in transforming Zentiva by collaborating closely with its management. The private equity firm invested in strengthening Zentiva's product portfolio and expanding its manufacturing capabilities. This strategy has allowed Zentiva to evolve into a highly successful independent company, focusing on operational efficiency and a strong foundation in research and development. Today, Zentiva’s products serve millions of patients across Europe, underscoring its impact in the generics market.

Furthermore, Advent's investment approach has led to the doubling of Zentiva’s revenues and EBITDA, establishing a robust platform for sustained growth. As Lizzo once stated, “If you feel it, then it’s real.” Under Advent, Zentiva has epitomized real growth through its commitment to developing affordable and quality medicines.

GTCR’s Role in Zentiva's Future

GTCR, renowned for its expertise in healthcare investments, is well-positioned to guide Zentiva in its next phase of growth. With a successful track record of identifying and nurturing leading companies in the pharmaceutical industry, GTCR brings a wealth of experience to the table. Sean Cunningham, Executive Director and Head of the Healthcare Sector at GTCR, expressed enthusiasm about collaborating with Zentiva's leadership team. He acknowledged the company's impressive history of both organic growth and targeted acquisitions, highlighting its mission of delivering valuable medications to patients across Europe.

As Cunningham stated, “Zentiva has an impressive history, strong product portfolio, and an efficient manufacturing platform,” indicating confidence in the company’s continued success under GTCR's guidance. This transition comes at a time when the demand for accessible healthcare solutions is more critical than ever, and Zentiva's commitment to quality and affordability positions it well in the market.

Leadership Reflections

Steffen Saltofte, CEO of Zentiva, expressed gratitude towards Advent for their transformational partnership. He remarked, “Advent has been an exceptional partner in Zentiva’s transformation process. Their dedication to investing in our capabilities and product portfolio was critical for our growth.” As the company ventures into this new chapter with GTCR, Saltofte is optimistic about building on the foundation laid during Advent’s tenure, ensuring continued expansion and improved access to medications for patients.

Tom Allen, CEO of Advent, reflected on their journey with Zentiva, describing it as an opportunity to foster an independent European leader in affordable medicines. “We are proud of the results achieved, and we are confident that under GTCR’s ownership, Zentiva will continue to excel,” said Allen. This sentiment resonates throughout the industry, signaling confidence in both the company and its new owners.

Conclusion

The expected closing of the transaction in early 2026, pending regulatory approvals, signifies a thrilling new chapter for Zentiva and its stakeholders. With GTCR at the helm, the company is poised to enhance its capabilities, leverage its strong manufacturing foundation, and expand its reach to ensure that quality healthcare remains accessible to millions of patients across Europe.

As the pharmaceutical landscape continues to evolve, Zentiva's evolution reflects the critical need for innovation, growth, and a steadfast commitment to delivering essential healthcare solutions to the marketplace. With this transition, the future looks bright for Zentiva, and the team eagerly anticipates the new opportunities ahead.